<div id="readability-page-1"><p>Oliver McCammon, an analyst from LifeSci Capital, maintained the Buy rating on Corbus Pharmaceuticals. The associated price target remains the same with $38.00.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Oliver McCammon has given his Buy rating due to a combination of factors tied to Corbus’s emerging oncology franchise and the strategic positioning of CRB-701. He views HPV-positive head and neck cancer as an underserved, expanding segment where current EGFR‑targeted bispecific antibodies in late‑stage studies appear ill‑suited, particularly given their exclusion of HPV‑positive patients or weaker activity in that subgroup. McCammon believes this creates a meaningful opening for an alternative modality like anetumab ravtansine‑based ADC CRB‑701, which mechanistically aligns with the cyclin‑driven biology of HPV‑positive tumors and could be better tolerated in a generally younger, fitter patient population.</p> <p>He expects upcoming Phase 1/2 data for CRB‑701, including at ASCO, to refine the risk‑reward profile and potentially validate this thesis, while also recognizing that investor interest is already building around the HPV‑positive HNSCC opportunity. In his view, Corbus’s cash position and burn rate provide an adequate runway to reach key value‑inflection points, supporting continued development of CRB‑701 and the broader pipeline without immediate financing pressure. Reflecting confidence in both the clinical strategy and market opportunity, McCammon reiterates a Buy rating and maintains his 12‑month price target at $38, unchanged from his prior valuation.</p> <p>According to TipRanks, McCammon is a 5-star analyst with an average return of <span>95.0%</span> and a 67.92% success rate. McCammon covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Monte Rosa Therapeutics, and Corbus Pharmaceuticals.</p> <p>In another report released today, Oppenheimer also reiterated a Buy rating on the stock with a $54.00 price target.</p></div>

CRBP

IBBQ

LABU

SBIO

<p>Analyst Oliver McCammon from LifeSci Capital has reiterated a Buy rating on Corbus Pharmaceuticals, maintaining a price target of $38. He believes Corbus's CRB-701 has significant potential in treating HPV-positive head and neck cancer, an underserved market. McCammon anticipates upcoming Phase 1/2 data to validate this outlook. He also notes Corbus's strong cash position supports ongoing development without immediate financing needs. Oppenheimer has similarly reiterated a Buy rating with a higher price target of $54. McCammon is recognized as a 5-star analyst with a strong track record in the Healthcare sector.</p>

Tip Ranks

Corbus Pharma

iShares Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Perspective Therapeutics

Monte Rosa Therapeutics

Oppenheimer

Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential